目的：通过回顾性分析佛山市第二人民医院(地方三甲医院)2009/2016年门诊处方中局部降眼压药物，分析过去8a该院青光眼药物使用频度和变化趋势。

方法：回顾性分析2009-01-01/2016-12-31于我院门诊就诊的所有青光眼患者局部抗青光眼药物使用情况。分年度比较各类药物处方频次百分比，单药与联合用药的构成比及用药频度。

结果：β-肾上腺素能受体阻滞剂的处方频次构成比由2009年的81.51%下降为2016年的69.37%； 拟胆碱能类药物由2009年的12.04%下降为2016年的3.78%； 前列腺素类衍生物由2009年的8.40%上升为2016年的31.40%； α2-肾上腺素能受体激动剂由2009年的0上升为2016年的29.44%； 局部碳酸酐酶抑制剂变化不大。单用一种药物的比例由2009年的65.83%，降为2016年的46.22%，两种药物联合使用的比例由2009年的32.49%增加为2016年的38.77%； 三种药物联合使用的比例在2009年时为1.68%，到2016年时为12.96%； 四种药物联合使用的比例在2009年时为0，到2016年时增为1.97%； 而五种药物联合使用属个别情况。

结论：局部青光眼药物使用频度发生了显著的变化。β-肾上腺素能受体阻滞剂和拟胆碱能类药物的使用频度逐年下降，前列腺素类衍生物和α2-肾上腺素能受体激动剂的使用频度逐年上升。单用一种药物的比例在逐年降低，联合用药的比例则在逐年增加。

METHODS: The data of topical anti-glaucoma medications in outpatients in our hospital were collected from January 1^st 2009 to December 31^st 2016. These data were analyzed retrospectively. The main outcome measures were the percentages of prescriptions for all kinds of anti-glaucoma medications, the ratio of the mono-therapy and combination therapies, and the defined daily doses.

RESULTS: The ratio of beta-adrenergic receptor blocker declined from 81.51% in 2009 to 69.37% in 2016. The use of cholinergic agent decreased from 12.04% in 2009 to 3.78% in 2016. The prostaglandin derivatives increased from 8.40% in 2009 to 31.40% in 2016. Alpha 2 adrenergic receptor agonists increased from 0 in 2009 to 29.44% in 2016. Local carbonic anhydrase inhibitors changed slightly. The proportion of mono-therapy was reduced from 65.83% in 2009 to 46.22% in 2016. The ration of two agents combination increased from 32.49% in 2009 to 38.77% in 2016. The three medications combination was increased from 1.68% in 2009 to 12.96% in 2016. The proportion of four medications combination increased from 0 in 2009 to 1.97% in 2016, while the combined use of five drugs was an isolated case.

CONCLUSION: The proportion of topical anti-glaucoma agents has changed remarkably. The beta-adrenergic receptor blockers and cholinergic medications are decreasing, while the prostaglandin derivatives and alpha 2 adrenergic receptor agonists are increasing. The proportion of mono-therapy is declining, while the combined therapies are rising.